Seeking Alpha

Novartis' (NVS -0.3%) Lucentis (which brought in $2.4B last year and is licensed for AMD, DME,...

Novartis' (NVS -0.3%) Lucentis (which brought in $2.4B last year and is licensed for AMD, DME, and RVO) gains EU approval as "the first and only licensed treatment that has been proven to restore vision" in myopic choroidal neovascularization patients. A pivotal trial showed a 14-letter improvement in the first year with a median of two injections. Genentech (RHHBY.OB -0.4%) has rights to the drug in the U.S. (Also: Goldman likes Eylea based on superiority of Lucentis in study)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs